February 14, 2019 09:12 AM EST
Startups
Pharma

Ra­maswamy's Ax­o­vant whips up a CNS spin­off with a $530M deal and a syn­di­cate of sup­port­ers

Natalie Grover

Reporter

Af­ter beef­ing up its ar­se­nal of gene ther­a­pies-in-de­vel­op­ment in De­cem­ber fol­low­ing the strik­ing fail­ures of its once-hyped de­men­tia and Alzheimer’s as­sets, Vivek Ra­maswamy’s Ax­o­vant …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

US spent $450B on drugs last year, CMS says, with new obe­si­ty and di­a­betes drugs adding to to­tal

No­var­tis, Ab­b­Vie and PhRMA se­cure 340B court win in West Vir­ginia

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

A service from the Financial Times